Trial Search Results

International Collaborative Gaucher Group (ICGG) Gaucher Registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.

The objectives of the Registry are:

- To enhance the understanding of the variability, progression, and natural history of Gaucher disease with the ultimate goal of better guiding and assessing therapeutic interventions;

- To provide the Gaucher medical community with recommendations for monitoring patients and to provide reports on patient outcomes to help optimize patient care; and

- To evaluate the long-term effectiveness of Cerezyme.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Genzyme, a Sanofi Company

Stanford Investigator(s):


Inclusion Criteria:

   - All patients with a confirmed diagnosis of Gaucher disease are eligible for inclusion
   in the Registry. Confirmed diagnosis is defined as a documented β-glucocerebrosidase
   deficiency and/or mutation in the β-glucocerebrosidase gene.

   - For all patients, appropriate patient authorization will be obtained.

Exclusion Criteria:

   - No exclusion criteria for participation in the ICGG Gaucher Registry.NOTE: Registry
   participation does not exclude participation in other clinical studies.

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305